C Diff News Today

A construct or cost index for tots. So you want to go in. Or have a nice me or a good nights sleep but you cant because youre suffering from heartburn then you came to the right place for three reasons first this is a clinic in the from building in berlin second im going to meet dr mark johnson and third this is in good shape. If. You look at. No one has to suffer from heartburn for a long time we have great medications and surgical options with good long term results. Its nice to have gastric a...

Topics Stomach acid blockers Opportunity or risk . ; Heartburn Expert interview; Surgery for heartburn; Acupressure Fast relief for everyday complaints;. A cool school or have a nice me or a good nights sleep but you cant because youre suffering from heartburn then you came to the right place for three reasons first this is seriously nick a me from being in berlin the second im going to meet dr mark johnson and third this is in good shape. Good luck and i hope. No one has to suffer from heartbur...

Learn about the FDA's approval of Zevtera (ceftobiprole medocaril sodium) for Staphylococcus aureus infections in adults and pediatric patients, including common side effects and precautions.

The guideline recommends fecal microbiota transplant in most cases of recurrent Clostridioides difficile infection but does not suggest fecal microbiota-based therapies for IBD or IBS.

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection.

Investigators from the guideline panel discuss the AGA’s recommendations regarding the use of fecal microbiota-based therapies for CDI, IBD, and IBS.

Participants given omadacycline had high fecal concentrations with a distinct microbiome profile compared to those in the vancomycin group, with study results calling attention to the importance of antibiotics’ impact on the gut microbiome.

After pushback on social media, Tina Joshi, PhD, spoke with Infection Control Today to clarify and explain her study, her lifelong research, and what she hopes IPs and other IPC personnel can take from them.

New research published in Infection Control & Hospital Epidemiology reveals that patients staying in a hospital bed previously occupied by someone with a Clostr

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.